BNP Paribas Financial Markets’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-1,552
| Closed | -$962 | – | 4529 |
|
|
2018
Q4 | $962 | Hold |
1,552
| – | – | ﹤0.01% | 3926 |
|
|
2018
Q3 | $2.02K | Hold |
1,552
| – | – | ﹤0.01% | 4256 |
|
|
2018
Q2 | $2.1K | Sell |
1,552
-6,586
| -81% | -$10.1K | ﹤0.01% | 4246 |
|
|
2018
Q1 | $11.8K | Buy |
8,138
+1,176
| +17% | +$2.46K | ﹤0.01% | 4002 |
|
|
2017
Q4 | $15.7K | Buy |
6,962
+4,578
| +192% | +$11.6K | ﹤0.01% | 3987 |
|
|
2017
Q3 | $8.11K | Sell |
2,384
-174
| -7% | -$585 | ﹤0.01% | 3921 |
|
|
2017
Q2 | $9.08K | Buy |
2,558
+2,517
| +6,139% | +$8.29K | ﹤0.01% | 3968 |
|
|
2017
Q1 | $139 | Sell |
41
-316
| -89% | -$1.23K | ﹤0.01% | 3979 |
|
|
2016
Q4 | $1.64K | Sell |
357
-1,180
| -77% | -$4.87K | ﹤0.01% | 3955 |
|
|
2016
Q3 | $6.52K | Buy |
1,537
+645
| +72% | +$2.09K | ﹤0.01% | 3331 |
|
|
2016
Q2 | $2.14K | Buy |
892
+890
| +44,500% | +$3.22K | ﹤0.01% | 3444 |
|
|
2016
Q1 | $9 | Sell |
2
-2,112
| -100% | -$8.17K | ﹤0.01% | 2653 |
|
|
2015
Q4 | $8.31K | Sell |
2,114
-47
| -2% | -$217 | ﹤0.01% | 3415 |
|
|
2015
Q3 | $8.36K | Buy |
2,161
+1,292
| +149% | +$5.93K | ﹤0.01% | 3445 |
|
|
2015
Q2 | $4K | Buy |
+869
| New | +$8.33K | ﹤0.01% | 3446 |
|
BNP Paribas Financial Markets's AST Position: Q1 2019 in Review
BNP Paribas Financial Markets sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 1,552 shares — an estimated $962 sold.
BNP Paribas Financial Markets first reported a position in AST in Q2 2015 and held it in 15 quarters. The position peaked at $15.7K in Q4 2017. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- BNP Paribas Financial Markets reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- BNP Paribas Financial Markets sold 1,552 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $962.
- BNP Paribas Financial Markets first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 15 quarters.
- BNP Paribas Financial Markets's Asterias Biotherapeutics Inc. Series A position peaked at $15.7K in Q4 2017.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2019, filed 25 Apr 2019.